Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Human immunodeficiency virus 1 5′-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations

Journal of General Virology(2023)10.1099/jgv.0.001898Source: DataRank Database

Human immunodeficiency virus 1 5′-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations is a research paper published in Journal of General Virology (2023). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

bioproject gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.37)OA: hybridTopics (23)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Philip L. Tzou ORCID,Soo‐Yon Rhee ORCID,Malaya K. Sahoo ORCID,Benjamin A. Pinsky ORCID,Miri Krupkin ORCID

Live enrichment

PubMed:37801004 PMC:PMC10721937 OpenAlex:https://openalex.org/W4387392959

NIAID NIH HHS

Grant: R21 AI147632

NIAID NIH HHS

Grant: R03 AI147682

NIAID NIH HHS

Grant: R03 AI146632

NIGMS NIH HHS

Grant: R35 GM145306

NIAID NIH HHS

Grant: U54 AI170856

FWCI

0.37

Citation Percentile

0.6%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1099/jgv.0.001898

publisherhttps://doi.org/10.1099/jgv.0.001898

publisherhttps://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.001898?crawler=true&mimetype=application/pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37801004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10721937

Fields of Study

HIV Research and TreatmentHIV/AIDS drug development and treatmentViral-associated cancers and disorders

MeSH Terms

HumansMutationNucleotidesHIV-1HIV InfectionsReverse Transcriptase InhibitorsAnti-HIV AgentsDrug Resistance, ViralHIV Reverse Transcriptase

Keywords

Resistance mutationReverse transcriptaseVirologyBiologyVirusMutationDrug resistanceGenBankGeneticsRNAGene

Sustainable Development Goals

SDG 0: Good health and well-being

Human immunodeficiency virus 1 5′-leader mutations in plasma viruses before and after the development of reverse transcriptase inhibitor-resistance mutations

FAIR Checklist

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)